Literature DB >> 3298130

Is the P388 murine tumor no longer adequate as a drug discovery model?

T H Corbett, F A Valeriote, L H Baker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3298130     DOI： 10.1007/BF00217664

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  27 in total

1.  SCREENING DATA FROM THE CANCER CHEMOTHERAPY NATIONAL SERVICE CENTER SCREENING LABORATORIES. XIV.

Authors:  J LEITER; B J ABBOTT; A R BOURKE; S A SCHEPARTZ; I WODINSKY
Journal:  Cancer Res       Date:  1963-08       Impact factor: 12.701

2.  Drug evaluation in experimental tumor systems: potential and limitations in 1961.

Authors:  H E SKIPPER
Journal:  Cancer Chemother Rep       Date:  1962-02

3.  Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure.

Authors:  T H Corbett; D P Griswold; B J Roberts; J C Peckham; F M Schabel
Journal:  Cancer Res       Date:  1975-09       Impact factor: 12.701

4.  Malignancy of somatic cell hybrids.

Authors:  B Ephrussi; R L Davidson; M C Weiss; H Harris; G Klein
Journal:  Nature       Date:  1969-12-27       Impact factor: 49.962

Review 5.  Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.

Authors:  J M Venditti; R A Wesley; J Plowman
Journal:  Adv Pharmacol Chemother       Date:  1984

6.  Experimental screening procedures and clinical predictability value.

Authors:  A Goldin; A A Serpick; N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-05

7.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

Authors:  T H Corbett; B J Roberts; W R Leopold; J C Peckham; L J Wilkoff; D P Griswold; F M Schabel
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

8.  Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.

Authors:  T H Corbett; M C Bissery; A Wozniak; J Plowman; L Polin; E Tapazoglou; J Dieckman; F Valeriote
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

9.  Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.

Authors:  M J Staquet; D P Byar; S B Green; M Rozencweig
Journal:  Cancer Treat Rep       Date:  1983-09

Review 10.  Patterns of response of animal tumors to anticancer agents. A systematic analysis of the literature in experimental cancer chemotherapy--1945-1958.

Authors:  E Hirschberg
Journal:  Cancer Res       Date:  1963-06       Impact factor: 12.701
View more
  23 in total

1.  Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice.

Authors:  L Polin; F Valeriote; K White; C Panchapor; S Pugh; J Knight; P LoRusso; M Hussain; E Liversidge; N Peltier; T Golakoti; G Patterson; R Moore; T H Corbett
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.

Authors:  P B Jensen; H Roed; T Skovsgaard; E Friche; L Vindeløv; H H Hansen; M Spang-Thomsen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  A new paradigm for the development of anticancer agents from natural products.

Authors:  Balanehru Subramanian; Alexander Nakeff; Karen Tenney; Phillip Crews; Leslie Gunatilaka; Fred Valeriote
Journal:  J Exp Ther Oncol       Date:  2006

4.  Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate.

Authors:  T H Corbett; P LoRusso; L Demchick; C Simpson; S Pugh; K White; J Kushner; L Polin; J Meyer; J Czarnecki; L Heilbrun; J P Horwitz; J L Gross; C H Behrens; B A Harrison; R J McRipley; G Trainor
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

5.  Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines.

Authors:  P B Jensen; H Roed; L Vindeløv; I J Christensen; H H Hansen
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

6.  Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice.

Authors:  Lisa Polin; Kathryn White; Juiwanna Kushner; Jennifer Paluch; Chiab Simpson; Susan Pugh; Matthew K Edelstein; Stuart Hazeldine; Joseph Fontana; Patricia LoRusso; Jerome P Horwitz; Thomas H Corbett
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

Review 7.  5-Fluorouracil containing combinations in murine tumor systems.

Authors:  T H Corbett; M C Bissery; P Mucci-LoRusso; L Polin
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

8.  Antitumor activity and mechanism of action of the marine compound girodazole.

Authors:  F Lavelle; A Zerial; C Fizames; B Rabault; A Curaudeau
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

Review 9.  Tumor models in drug development.

Authors:  D P Griswold; S D Harrison
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

10.  In vitro activity of amonafide against primary human tumors compared with the activity of standard agents.

Authors:  J A Ajani; F L Baker; G Spitzer
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.